KALV · Insider Trading
KalVista Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by KALV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | Bilal Arif | Chief Operations Officer | D | −149,000 deriv. | — |
| 2026-06-11 | Laurence Reid | Director | D | −17,000 deriv. | — |
| 2026-06-11 | Patrick Treanor | Director | D | −67,000 deriv. | — |
| 2026-06-11 | Paul K. Audhya | CHIEF MEDICAL OFFICER | D | −150,260 | — |
| 2026-06-11 | Brian Piekos | Chief Financial Officer | D | −21,661 | — |
| 2026-06-11 | Nicole Sweeny | Chief Commercial Officer | D | −59,291 | — |
| 2026-06-11 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | D | −229,918 | — |
| 2026-06-11 | Bethany Sensenig | Director | D | −45,000 deriv. | — |
| 2026-06-11 | William Fairey | Director | D | −57,000 deriv. | — |
| 2026-06-11 | Nancy Stuart | Director | D | −74,000 deriv. | — |
| 2026-06-11 | Brian JG Pereira | Director | D | −91,000 deriv. | — |
| 2026-06-11 | Edward W Unkart | Director | D | −109,000 deriv. | — |
| 2026-06-11 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | D | −479,989 | — |
| 2026-05-29 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | −$666.26K |
| 2026-05-27 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +2,761 | −$59.96K |
| 2026-05-27 | Nicole Sweeny | Chief Commercial Officer | MIXED | +3,511 | −$39.87K |
| 2026-05-27 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | +1,159 | −$52.65K |
| 2026-05-26 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +12,324 | −$292.65K |
| 2026-05-26 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | +1,392 | −$63.16K |
| 2026-05-26 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +3,565 | −$71.92K |
| 2026-05-26 | Nicole Sweeny | Chief Commercial Officer | MIXED | +4,389 | −$49.85K |
| 2026-05-26 | Brian Piekos | Chief Financial Officer | MIXED | +3,511 | −$39.88K |
| 2026-05-19 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | +666 | −$29.65K |
| 2026-05-19 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +1,290 | −$30.21K |
| 2026-05-19 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +1,387 | −$27.62K |
| 2026-05-13 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +3,798 | −$88.73K |
| 2026-04-20 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +3,564 | −$54.30K |
| 2026-04-20 | Brian Piekos | Chief Financial Officer | MIXED | +4,388 | −$37.64K |
| 2026-04-20 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +10,762 | −$193.07K |
| 2026-04-20 | Nicole Sweeny | Chief Commercial Officer | MIXED | +4,388 | −$37.64K |
| 2026-03-27 | Venrock Healthcare Capital Partners EG, L.P. | 10%+ Owner | Sell | −1,502,417 | −$25.84M |
| 2026-03-10 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +8,932 | −$107.63K |
| 2026-02-24 | Brian Piekos | Chief Financial Officer | MIXED | +3,233 | −$27.51K |
| 2026-02-24 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +13,216 | −$156.20K |
| 2026-02-24 | Nicole Sweeny | Chief Commercial Officer | MIXED | +7,275 | −$61.88K |
| 2026-02-24 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | +2,528 | −$67.67K |
| 2026-02-24 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +5,896 | −$83.34K |
| 2026-02-19 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +1,381 | −$15.57K |
| 2026-02-19 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | +665 | −$16.64K |
| 2026-02-19 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | +1,256 | −$17.45K |
| 2026-02-13 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +3,766 | −$52.66K |
| 2026-01-21 | Paul K. Audhya | CHIEF MEDICAL OFFICER | A | +100,000 deriv. | — |
| 2026-01-21 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | A | +325,000 deriv. | — |
| 2026-01-21 | Brian Piekos | Chief Financial Officer | A | +100,000 deriv. | — |
| 2026-01-21 | Nicole Sweeny | Chief Commercial Officer | A | +100,000 deriv. | — |
| 2026-01-21 | Bilal Arif | Chief Operations Officer | A | +49,000 deriv. | — |
| 2025-12-09 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +8,331 | −$120.42K |
| 2025-12-04 | Nicole Sweeny | Chief Commercial Officer | MIXED | +7,437 | −$51.29K |
| 2025-11-26 | Brian Piekos | Chief Financial Officer | MIXED | +10,529 | −$60.14K |
| 2025-11-26 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | +12,310 | −$147.15K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bong Y Koh | 10%+ Owner | 5,303,985 | $143.21M |
| VHCP Co-Investment Holdings III, LLC | 10%+ Owner | 5,278,985 | $142.53M |
| VHCP Management EG, LLC | 10%+ Owner | 5,117,285 | $138.17M |
| Venrock Healthcare Capital Partners EG, L.P. | 10%+ Owner | 5,089,354 | $137.41M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KALV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.